Dose Escalation Methods in Phase I Cancer Clinical TrialsChristophe Le Tourneau, Lillian L. Siu|JNCI Journal of the National Cancer Institute|2009Cited by 856
Toward understanding and exploiting tumor heterogeneityAsh A. Alizadeh, Jessica Zucman‐Rossi, Victoria Aranda et al.|Nature Medicine|2015Cited by 770
Small molecules, big impact: 20 years of targeted therapy in oncologyPhilippe L. Bédard, Lillian L. Siu, David M. Hyman et al.|The Lancet|2020Cited by 606
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupAnne W.M. Lee, Joseph T. F. Lau, W.H. Lau et al.|Journal of Clinical Oncology|2005Cited by 448
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Alain P. Algazi et al.|European Journal of Cancer|2018Cited by 267